β-glycosphingolipids as immune modulators

Journal of Immunotoxicology

Volumn 5, Issue 2, 2008, Pages 209-220

  Adar, Tomer ^a   Ilan, Yaron ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Glycosphingolipids; Ligands; NKT cells

Indexed keywords

BETA GLYCOSPHINGOLIPID; CYTOKINE; GAMMA INTERFERON; GLYCOSPHINGOLIPID; INTERLEUKIN 13; INTERLEUKIN 4; LIGAND; T LYMPHOCYTE RECEPTOR;

ADOPTIVE TRANSFER; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COLITIS; CONFERENCE PAPER; DIABETES MELLITUS; ENCEPHALITIS; GRAFT VERSUS HOST REACTION; HEPATITIS B; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INFECTION; LIGAND BINDING; LIVER CELL CARCINOMA; LYMPHOCYTE COUNT; MALARIA; MULTIPLE SCLEROSIS; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; RHEUMATOID ARTHRITIS; SCLERODERMA; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TUBERCULOSIS;

ANIMALS; ANTIGENS, CD1; AUTOIMMUNE DISEASES; GLYCOSPHINGOLIPIDS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; NEOPLASMS; T-LYMPHOCYTES;

EID: 45849085039     PISSN: 1547691X     EISSN: 1547691X     Source Type: Journal    
DOI: 10.1080/15476910802129620     Document Type: Conference Paper

References (121)

1. Adar, T., Ben-Ami, R., Elstein, D., Zimran, A., Berliner, S., Yedgar, S., and Barshtein, G. 2006. Aggregation of red blood cells in patients with Gaucher disease. Br. J. Haematol. 134:432-437.
2. Apostolou, I., Takahama, Y., Belmant, C., Kawano, T., Huerre, M., Marchal, G., Cui, J., Taniguchi, M., Nakauchi, H., Fournie, J. J., Kourilsky, P., and Gachelin, G. 1999. Murine natural killer T(NKT)-cells [correction of natural killer cells] contribute to the granulomatous reaction caused by mycobacterial cell walls. Proc. Natl. Acad. Sci. USA 96:5141-5146.
3. - thymocytes with specific lymphokine secretion. Eur. J. Immunol. 23:307-310.
4. + T-lymphocytes. Science 268:863-865.
5. Bendelac, A., Rivera, M. N., Park, S. H., and Roark, J. H. Mouse 1997. CD1-specific NK1 T-cells: Development, specificity, and function. Annu. Rev. Immunol. 15:535-562.
6. Bendelac, A., Savage, P. B., and Teyton, L. 2007. The biology of NKT cells. Annu. Rev. Immunol. 25:297-336.
7. Berzins, S. P., Smyth, M. J., and Godfrey, D. I. 2005. Working with NKT cells - pitfalls and practicalities. Curr. Opin. Immunol.17:448-454.
8. Bezbradica, J. S., Stanic, A. K., Matsuki, N., Bour-Jordan, H., Bluestone, J. A., Thomas, J. W., Unutmaz, D., Van Kaer, L., and Joyce, S. 2005. Distinct roles of dendritic cells and B-cells in Vα14Jα18 natural T-cell activation in vivo. J. Immunol. 174:4696-4705.
9. Bittman, R. 2004. The 2003 ASBMB-Avanti Award in Lipids Address: Applications of novel synthetic lipids to biological problems. Chem. Phys. Lipids 129:111-131.
10. Brigl, M., and Brenner, M. B. 2004. CD1: Antigen presentation and T-cell function. Annu. Rev. Immunol. 22:817-890.
11. Brockman, H. L., Momsen, M. M., Brown, R. E., He, L., Chun, J., Byun, H. S., and Bittman, R. 2004. The 4,5-double bond of ceramide regulates its dipole potential, elastic properties, and packing behavior. Biophys. J. 87:1722-1731.
12. Brossay, L., Chioda, M., Burdin, N., Koezuka, Y., Casorati, G., Dellabona, P., and Kronenberg, M. 1998. CD1d-mediated recognition of an α-galactosylceramide by natural killer T-cells is highly conserved through mammalian evolution. J. Exp. Med. 188:1521-1528.
13. Brossay, L., Jullien, D., Cardell, S., Sydora, B. C., Burdin, N., Modlin, R. L., and Kronenberg, M. 1997. Mouse CD1 is mainly expressed on hemopoietic-derived cells. J. Immunol. 159:1216-1224.
14. Brutkiewicz, R. R. 2006. CD1d ligands: The good, the bad, and the ugly. J. Immunol. 177:769-775.
15. H2 cytokine synthesis. Eur. J. Immunol. 1999;29:2014-2025.
16. Carnaud, C., Lee, D., Donnars, O., Park, S. H., Beavis, A., Koezuka, Y., and Bendelac, A. 1999. Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163:4647-4650.
17. Chackerian, A., Alt, J., Perera, V., and Behar, S. M. 2002. Activation of NKT cells protects mice from tuberculosis. Infect. Immun. 70:6302-6309.
18. Chang, Y. J., Huang, J. R., Tsai, Y. C., Hung, J. T., Wu, D., Fujio, M., Wong, C. H., and Yu, A. L. 2007. Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids. Proc. Natl. Acad. Sci. USA 104:10299-10304.
19. Crispe, I. N. 2003. Hepatic T-cells and liver tolerance. Nat. Rev. Immunol. 3:51-62.
20. Crowe, N. Y., Smyth, M. J., and Godfrey, D. I. 2002. A critical role for natural killer T-cells in immunosurveillance of methylcholanthrene-induced sarcomas. J. Exp. Med. 196:119-127.
21. Cui, J., Watanabe, N., Kawano, T., Yamashita, M., Kamata, T., Shimizu, C., Kimura, M., Shimizu, E., Koike, J., Koseki, H., Tanaka, Y., Taniguchi, M., and Nakayama, T. 1999. Inhibition of T-helper cell type 2 cell differentiation and immunoglobulin E response by ligand-activated Vα14 natural killer T-cells. J. Exp. Med. 190:783-792.
22. De Silva, A. D., Park, J. J., Matsuki, N., Stanic, A. K., Brutkiewicz, R. R., Medof, M. E., and Joyce, S. 2002. Lipid protein interactions: The assembly of CD1d1 with cellular phospholipids occurs in the endoplasmic reticulum. J. Immunol. 168:723-733.
23. - T-cells. J. Exp. Med. 180:1171-1176.
24. H0 cytokine secretion patterns. J. Immunol. 163:2314-2321.
25. + T-cells upon NK T- or T-cell activation. J. Immunol. 165:4305-4311.
26. Eberl, G., and MacDonald, H. R. 1998. Rapid death and regeneration of NKT cells in anti-CD3ε- or IL-12-treated mice: A major role for bone marrow in NKT cell homeostasis. Immunity 9:345-353.
27. Elstein D, Abrahamov A, Hadas-Halpern I, and Zimran, A. 2001. Gaucher's disease. Lancet 358:324-327.
28. Gansert, J. L., Kiessler, V., Engele, M., Wittke, F., Rollinghoff, M., Krensky, A. M., Porcelli, S. A., Modlin, R. L., and Stenger, S. 2003. Human NKT cells express granulysin and exhibit antimycobacterial activity. J. Immunol. 170:3154-3161.
29. Giabbai, B., Sidobre, S., Crispin, M. D., Sanchez-Ruiz, Y., Bachi, A., Kronenberg, M., Wilson, I. A., and Degano, M. 2005. Crystal structure of mouse CD1d bound to the self ligand phosphatidylcholine: A molecular basis for NKT cell activation. J. Immunol. 175:977-984.
30. Godfrey, D. I., Hammond, K. J., Poulton, L. D., Smyth, M. J., and Baxter, A. G. 2000. NKT cells: Facts, functions and fallacies. Immunol. Today 21:573-583.
31. Godfrey, D. I., and Kronenberg, M. 2004. Going both ways: Immune regulation via CD1d-dependent NKT cells. J. Clin. Invest. 114:1379-1388.
32. Godfrey, D. I., MacDonald, H. R., Kronenberg, M., Smyth, M. J., and Van Kaer, L. 2004. NKT cells: What's in a name? Nat. Rev. Immunol. 4:231-237.
33. Godfrey, D. I., McConville, M. J., and Pellicci, D. G. 2006. Chewing the fat on natural killer T-cell development. J. Exp. Med. 203:2229-2232.
34. Goni, F. M., and Alonso, A. 2006. Biophysics of sphingolipids I. Membrane properties of sphingosine, ceramides and other simple sphingolipids. Biochim. Biophys. Acta 1758:1902-1921.
35. Gonzalez-Aseguinolaza, G., de Oliveira, C., Tomaska, M., Hong, S., Bruna-Romero, O., Nakayama, T., Taniguchi, M., Bendelac, A., Van Kaer, L., Koezuka, Y., and Tsuji, M. 2000. α-galactosylceramide-activated Vα14 natural killer T-cells mediate protection against murine malaria. Proc. Natl. Acad. Sci. USA 97:8461-8466.
36. Gonzalez-Aseguinolaza, G., Van Kaer, L., Bergmann, C. C., Wilson, J. M., Schmieg, J., Kronenberg, M., Nakayama, T., Taniguchi, M., Koezuka, Y., and Tsuji, M. 2002. Natural killer T-cell ligand α-galactosylceramide enhances protective immunity induced by malaria vaccines. J. Exp. Med. 195:617-624.
37. Gumperz, J. E., and Brenner, M. B. 2001. CD1-specific T-cells in microbial immunity. Curr. Opin. Immunol. 13:471-478.
38. - (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J. Exp. Med. 1998; 187:1047-1056.
39. Hansen, D. S., and Schofield, L. 2004. Regulation of immunity and pathogenesis in infectious diseases by CD1d-restricted NKT cells. Int. J. Parasitol. 34:15-25.
40. Hauben, E., Roncarolo, M. G., Nevo, U., and Schwartz, M. 2005. Beneficial autoimmunity in Type 1 diabetes mellitus. Trends Immunol. 26:248-253.
41. + T-cell subsets: A subset (Thy0) that secretes diverse cytokines and over-expresses the Vβ8 T-cell receptor gene family. J. Exp. Med. 176:269-274.
42. + T-cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J. Immunol. 171:5140-5147.
43. Hong, S., Wilson, M. T., Serizawa, I., Wu, L., Singh, N., Naidenko, O. V., Miura, T., Haba, T., Scherer, D. C., Wei, J., Kronenberg, M., Koezuka, Y., and Van Kaer, L. 2001. The natural killer T-cell ligand α- galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat. Med. 7:1052-1056.
44. Ilan, Y., Ohana, M., Pappo, O., Margalit, M., Lalazar, G., Engelhardt, D., Rabbani, E., and Nagler, A. 2007. Alleviation of acute and chronic graft-versus-host disease in a murine model is associated with glucocerebroside-enhanced natural killer T-lymphocyte plasticity. Transplantation 83:458-467.
45. Ishihara, S., Nieda, M., Kitayama, J., Osada, T., Yabe, T., Ishikawa, Y., Nagawa, H., Muto, T., and Juji, T. 1999. CD8(+)NKR-P1A(+) T-cells preferentially accumulate in human liver. Eur. J. Immunol. 29:2406-2413.
46. Iwamura, C., and Nakayama, T. 2007. Role of α-galactosylceramide- activated Vα14 natural killer T-cells in the regulation of allergic diseases. Allergol. Int. 56:1-6.
47. Jahng, A. W., Maricic, I., Pedersen, B., Burdin, N., Naidenko, O., Kronenberg, M., Koezuka, Y., and Kumar, V. 2001. Activation of natural killer T-cells potentiates or prevents experimental autoimmune encephalomyelitis. J. Exp. Med. 194:1789-1799.
48. Jinquan, T., Li, W., Yuling, H., and Lang, C. 2006. All roads lead to Rome: Pathways of NKT cells promoting asthma. Arch. Immunol. Ther. Exp. (Warsz.) 54:335-340.
49. Kakimi, K., Guidotti, L. G., Koezuka, Y., and Chisari, F. V. 2000. Natural killer T-cell activation inhibits hepatitis B virus replication in vivo. J. Exp. Med. 192:921-930.
50. H1 response and local host resistance in mice infected with Cryptococcus neoformans. Infect. Immun. 69:213-220.
51. Kawakami, K., Kinjo, Y., Yara, S., Uezu, K., Koguchi, Y., Tohyama, M., Azuma, M., Takeda, K., Akira, S., and Saito, A. 2001b. Enhanced γ-interferon production through activation of Vα14(+) natural killer T-cells by α-galactosylceramide in IL-18-deficient mice with systemic cryptococcosis. Infect. Immun. 69:6643-6650.
52. Kawakami, K., Tohyama, M., Qifeng, X., and Saito, A. 1997. Expression of cytokines and inducible nitric oxide synthase mRNA in the lungs of mice infected with Cryptococcus neoformans: Effects of IL-12. Infect. Immun. 65:1307-1312.
53. Kawano, T., Cui, J., Koezuka, Y., Toura, I., Kaneko, Y., Motoki, K., Ueno, H., Nakagawa, R., Sato, H., Kondo, E., Koseki, H., and Taniguchi, M. 1997. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 278:1626-1629.
54. Kinjo, Y., and Kronenberg, M. 2005. Vα14i NKT cells are innate lymphocytes that participate in the immune response to diverse microbes. J. Clin. Immunol. 25:522-533.
55. Kitamura, H., Iwakabe, K., Yahata, T., Nishimura, S., Ohta, A., Ohmi, Y., Sato, M., Takeda, K., Okumura, K., Van Kaer, L., Kawano, T., Taniguchi, M., and Nishimura, T. 1999. The natural killer T (NKT)-cell ligand α- galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J. Exp. Med. 189:1121-1128.
56. Kronenberg, M., and Engel, I. 2007. On the road: Progress in finding the unique pathway of invariant NKT cell differentiation. Curr. Opin. Immunol 19:186-193.
57. H2 paradigm. J. Hepatology 44:S237.
58. Lalazar, G., Preston, S., Zigmond, E., Ben Yaacov, A., and Ilan, Y. 2006b. Glycolipids as immune modulatory tools. Mini Rev. Med. Chem. 6:1249-1253.
59. Laloux, V., Beaudoin, L., Ronet, C., and Lehuen, A. 2002. Phenotypic and functional differences between NKT cells colonizing splanchnic and peripheral lymph nodes. J. Immunol. 168:3251-3258.
60. Liu, Y., and Bittman, R. 2006. Synthesis of fluorescent lactosylceramide stereoisomers. Chem. Phys. Lipids 142:58-69.
61. H1-biased responses in human natural killer T-cells. Chembiochem 7:1750-1756.
62. Margalit, M., Ghazala, S. A., Alper, R., Elinav, E., Klein, A., Doviner, V., Sherman, Y., Thalenfeld, B., Engelhardt, D., Rabbani, E., and Ilan, Y. 2005. Glucocerebroside treatment ameliorates ConA hepatitis by inhibition of NKT lymphocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 289:G917-925.
63. Matsuda, J. L., Naidenko, O. V., Gapin, L., Nakayama, T., Taniguchi, M., Wang, C. R., Koezuka, Y., and Kronenberg, M. 2000. Tracking the response of natural killer T-cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med. 192:741-754.
64. rd, Zhou, D., Saint-Mezard, P., Wang, V., Gao, Y., Yin, N., Hoebe, K., Schneewind, O., Walker, D., Beutler, B., Teyton, L., Savage, P. B., and Bendelac, A. 2005. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434:525-529.
65. + lymphocytes in immune-mediated colitis: A pro-inflammatory or a tolerizing subgroup of cells? Microbes Infect. 7:825-835.
66. Meyer, E. H., DeKruyff, R. H., and Umetsu, D. T. 2007. iNKT cells in allergic disease. Curr. Top. Microbiol. Immunol. 314:269-291.
67. Miyake, S., and Yamamura, T. 2007. NKT cells and autoimmune diseases: Unraveling the complexity. Curr. Top. Microbiol. Immunol. 314:251-267.
68. Miyake, S., and Yamamura, T. 2005. Therapeutic potential of glycolipid ligands for natural killer (NK) T-cells in the suppression of autoimmune diseases. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5:315-322.
69. H2 bias of natural killer T-cells. Nature 413:531-534.
70. Morel, P. A., Feili-Hariri, M., Coates, P. T., and Thomson, A. W. 2003. Dendritic cells, T-cell tolerance and therapy of adverse immune reactions. Clin. Exp. Immunol. 133:1-10.
71. Motsinger, A., Azimzadeh, A., Stanic, A. K., Johnson, R. P., Van Kaer, L., Joyce, S., and Unutmaz, D. 2003. Identification and simian immunodeficiency virus infection of CD1d-restricted macaque natural killer T-cells. J. Virol. 77:8153-8158.
72. Nishimura, T., Kitamura, H., Iwakabe, K., Yahata, T., Ohta, A., Sato, M., Takeda, K., Okumura, K., Van Kaer, L., Kawano, T., Taniguchi, M., Nakui, M., Sekimoto, M., and Koda, T. 2000. The interface between innate and acquired immunity: Glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T-lymphocytes. Int. Immunol. 12:987-994.
73. Novak, J., Griseri, T., Beaudoin, L., and Lehuen, A. 2007. Regulation of type 1 diabetes by NKT cells. Int. Rev. Immunol. 26:49-72.
74. + cells in the liver of mice. J. Exp. Med. 180:699-704.
75. Ortaldo, J. R., Young, H. A., Winkler-Pickett, R. T., Bere, E. W., Jr., Murphy, W. J., and Wiltrout, R. H. 2004. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides. J. Immunol. 172:943-953.
76. Osman, Y., Kawamura, T., Naito, T., Takeda, K., Van Kaer, L., Okumura, K., and Abo, T. 2000. Activation of hepatic NKT cells and subsequent liver injury following administration of α-galactosylceramide. Eur. J. Immunol. 30:1919-1928.
77. Parekh, V. V., Singh, A. K., Wilson, M. T., Olivares-Villagomez, D., Bezbradica, J. S., Inazawa, H., Ehara, H., Sakai, T., Serizawa, I., Wu, L., Wang, C. R., Joyce, S., and Van Kaer, L. 2004. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct α- and β-anomeric glycolipids. J. Immunol. 173:3693-3706.
78. Park, Y. K., Lee, J. W., Ko, Y. G., Hong, S., and Park, S. H. 2005. Lipid rafts are required for efficient signal transduction by CD1d. Biochem. Biophys. Res. Commun. 327:1143-1154.
79. -α/β T-cells demonstrates preferential use of several Vβ genes and an invariant TCR α chain. J. Exp. Med. 178:1-16.
80. Porubsky, S., Speak, A. O., Luckow, B., Cerundolo, V., Platt, F. M., and Grone, H. J. 2007. Normal development and function of invariant natural killer T-cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. Proc. Natl. Acad. Sci. USA 104:5977-5982.
81. Prohaska, S. S., Scherer, D. C., Weissman, I. L., and Kondo, M. 2002. Developmental plasticity of lymphoid progenitors. Sem. Immunol. 14:377-384.
82. Roark, J. H., Park, S. H., Jayawardena, J., Kavita, U., Shannon, M., and Bendelac, A. 1998. CD1.1 expression by mouse antigen-presenting cells and marginal zone B-cells. J. Immunol. 160:3121-3127.
83. Rothenberg, E. V., and Dionne, C. J. 2002. Lineage plasticity and commitment in T-cell development. Immunol. Rev. 187:96-115.
84. Rothenberg, E. V. 2007. Negotiation of the T-lineage fate decision by transcription-factor interplay and microenvironmental signals. Immunity 26:690-702.
85. Safadi, R., Zigmond, E., Pappo, O., Shalev, Z., and Ilan, Y. 2007. Amelioration of hepatic fibrosis via β-glucosylceramide-mediated immune modulation is associated with altered CD8 and NKT lymphocyte distribution. Int. Immunol. 19:1021-1029.
86. Schmieg, J., Yang, G., Franck, R. W., Van Rooijen, N., and Tsuji, M. 2005. Glycolipid presentation to natural killer T-cells differs in an organ-dependent fashion. Proc. Natl. Acad. Sci. USA 102:1127-1132.
87. Sehgal, P. B. 2003. Plasma membrane rafts and chaperones in cytokine/STAT signaling. Acta Biochim. Pol. 50:583-594.
88. + lymphocytes. Oncology 66:323-330.
89. Shibolet, O., Kalish, Y., Klein, A., Alper, R., Zolotarov, L., Thalenfeld, B., Engelhardt, D., Rabbani, E., and Ilan, Y. 2004b. Adoptive transfer of ex vivo immune-programmed NKT lymphocytes alleviates immune-mediated colitis. J. Leukocyte Biol. 75:76-86.
90. H2 phenotype. J. Immunol. 163:2373-2377.
91. Singh, R. D., Puri, V., Valiyaveettil, J. T., Marks, D. L., Bittman, R., and Pagano, R. E. 2003. Selective caveolin-1-dependent endocytosis of glycosphingolipids. Mol. Biol. Cell 14:3254-3265.
92. Skold, M., and Behar, S. M. 2003. Role of CD1d-restricted NKT cells in microbial immunity. Infect. Immun. 71:5447-5455.
93. Smyth, M. J., Thia, K. Y., Street, S. E., Cretney, E., Trapani, J. A., Taniguchi, M., Kawano, T., Pelikan, S. B., Crowe, N. Y., and Godfrey, D. I. 2000. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191:661-668.
94. Sonnino, S., Mauri, L., Chigorno, V., and Prinetti, A. 2007. Gangliosides as components of lipid membrane domains. Glycobiology 17:1R-13R.
95. + T-cell lymphoma by natural killer T (NKT)-cells. Proc. Natl. Acad. Sci. USA 2002; 99:8197-8202.
96. Stanic, A. K., De Silva, A. D., Park, J. J., Sriram, V., Ichikawa, S., Hirabyashi, Y., Hayakawa, K., Van Kaer, L., Brutkiewicz, R. R., and Joyce, S. 2003a. Defective presentation of the CD1d1-restricted natural Vα14Jα18 NKT lymphocyte antigen caused by β-D-glucosylceramide synthase deficiency. Proc. Natl. Acad. Sci. USA 100:1849-1854.
97. Stanic, A. K., Park, J. J., and Joyce, S. 2003b. Innate self-recognition by an invariant, rearranged T-cell receptor and its immune consequences. Immunology 109:171-184.
98. Stenger, S., Hanson, D. A., Teitelbaum, R., Dewan, P., Niazi, K. R., Froelich, C. J., Ganz, T., Thoma-Uszynski, S., Melian, A., Bogdan, C., Porcelli, S. A., Bloom, B. R., Krensky, A. M., and Modlin, R. L. 1998. An antimicrobial activity of cytolytic T-cells mediated by granulysin. Science 282:121-125.
99. + memory Tcells: Functional differentiation and homeostasis. Immunol. Rev. 211:39-48.
100. Taniguchi, M., Harada, M., Kojo, S., Nakayama, T., and Wakao, H. 2003. The regulatory role of Vα14 NKT cells in innate and acquired immune response. Annu. Rev. Immunol. 21:483-513.
101. Taniguchi, M., and Nakayama, T. 2000. Recognition and function of Vα14 NKT cells. Sem. Immunol. 12:543-550.
102. Terabe, M., and Berzofsky, J. A. 2004. Immunoregulatory T-cells in tumor immunity. Curr. Opin. Immunol. 16:157-162.
103. + cells in oral immunoregulation of experimental colitis. Inflamm. Bowel Dis. 9:75-86.
104. Trop, S., Samsonov, D., Gotsman, I., Alper, R., Diment, J., and Ilan, Y. 1999. Liver-associated lymphocytes expressing NK1.1 are essential for oral immune tolerance induction in a murine model. Hepatology 29:746-755.
105. Tsuji, M. 2006. Glycolipids and phospholipids as natural CD1d-binding NKT cell ligands. Cell. Mol. Life Sci. 63:1889-1898.
106. Tupin, E., Kinjo, Y., and Kronenberg, M. 2007. The unique role of natural killer T-cells in the response to microorganisms. Nat. Rev. Microbiol. 5:405-417.
107. Ulrichs, T., and Porcelli, S. A. 2000. CD1 proteins: Targets of T-cell recognition in innate and adaptive immunity. Rev. Immunogenet. 2:416-432.
108. Van Kaer, L. 2004a. Natural killer T-cells as targets for immunotherapy of autoimmune diseases. Immunol. Cell Biol. 82:315-322.
109. Van Kaer, L. 2004b. Regulation of immune responses by CD1d-restricted natural killer T-cells. Immunol. Res. 30:139-153.
110. Van Kaer, L. 2005. α-Galactosylceramide therapy for autoimmune diseases: Prospects and obstacles. Nat. Rev. Immunol. 5:31-42.
111. Van Kaer, L. 2007. NKT cells: T-lymphocytes with innate effector functions. Curr. Opin. Immunol. 19:354-364.
112. H17: An effector CD4 T-cell lineage with regulatory T-cell ties. Immunity 24:677-688.
113. Wilson, M. T., Singh, A. K., and Van Kaer, L. 2002. Immunotherapy with ligands of natural killer T-cells. Trends Mol. Med. 8:225-231.
114. Wilson, M. T., and Van Kaer, L. 2003. Natural killer T-cells as targets for therapeutic intervention in autoimmune diseases. Curr. Pharm. Des. 9:201-220.
115. Yamamura, T., Miyamoto, K., Illes, Z., Pal, E., Araki, M., and Miyake, S. 2004. NKT cell-stimulating synthetic glycolipids as potential therapeutics for autoimmune disease. Curr. Top. Med. Chem. 4:561-567.
116. Yu, K. O., Im, J. S., Molano, A., Dutronc, Y., Illarionov, P. A., Forestier, C., Fujiwara, N., Arias, I., Miyake, S., Yamamura, T., Chang, Y. T., Besra, G. S., and Porcelli, S. A. 2005. Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of α-galactosylceramides. Proc. Natl. Acad. Sci. USA 102:3383-3388.
117. rd, Mattner, J., Zhou, D., Savage, P. B., Bendelac, A., Wilson, I. A., and Teyton, L. 2005. Structure and function of a potent agonist for the semi-invariant natural killer T-cell receptor. Nat. Immunol. 6:810-818.
118. Zhou, D. 2006. The immunological function of iGb3. Curr. Protein Pept. Sci. 7:325-333.
119. rd, Schrantz, N., Yin, N., Gao, Y., Sagiv, Y., Hudspeth, K., Wu, Y. P., Yamashita, T., Teneberg, S., Wang, D., Proia, R. L., Levery, S. B., Savage, P. B., Teyton, L., and Bendelac, A. 2004. Lysosomal glycosphingolipid recognition by NKT cells. Science 306:1786-1789.
120. Zigmond, E., Preston, S., Pappo, O., Lalazar, G., Margalit, M., Shalev, Z., Zolotarov, L., Friedman, D., Alper, R., and Ilan, Y. 2007. β-Glucosylceramide: A novel method for enhancement of natural killer T-lymphocyte plasticity in murine models of immune-mediated disorders. Gut 2007; 56:82-89.
121. - T-cells produce IL-4. J. Immunol. 149:1211-1215.